Varicella zoster
The present application relates to compositions capable of inducing an immune response against Varicella zoster virus, methods of administering such compositions, and methods of producing such compositions.
1 . An immunogenic composition comprising:
a varicella zoster virus antigen, wherein the varicella zoster virus antigen has the sequence of SEQ ID No. 9, and a compound of Formula I-4:
or a pharmaceutically acceptable salt thereof.
2 . The immunogenic composition of claim 1 ,
wherein the compound of Formula I-4 is in free acid form.
3 . The immunogenic composition of claim 1 ,
wherein the compound of Formula I-4 is in choline salt form.
4 . The immunogenic composition of claim 1 ,
further comprising a TLR4 agonist.
5 . The immunogenic composition of claim 4 ,
further comprising a liposome-forming compound.
6 . The immunogenic composition of claim 5 ,
wherein the liposome-forming compound forms liposomes containing the TLR4 agonist.
7 . The immunogenic composition of claim 5 ,
wherein the liposome-forming compound is selected from the group consisting of DOPC, DMPC, DMPG, cholesterol, and combinations thereof.
8 . The immunogenic composition according to claim 4 ,
further comprising an emulsion.
9 . The immunogenic composition according to claim 8 ,
wherein the emulsion is an oil-in-water emulsion.
10 . The immunogenic composition according to claim 8 ,
wherein the emulsion contains the compound of Formula I-4 pharmaceutically acceptable salt thereof.
11 . The immunogenic composition according to claim 10 ,
wherein the emulsion contains the TLR4 agonist.
12 . The immunogenic composition according to claim 6 ,
further comprising an emulsion.
13 . The immunogenic composition according to claim 12 ,
wherein the emulsion is an oil-in-water emulsion.
14 . The immunogenic composition according to claim 12 ,
wherein the emulsion contains the compound of Formula I-4 or pharmaceutically acceptable salt thereof.
15 . A method of increasing cell-mediated immunity in a patient, said method comprising administering to said patient an effective amount of an immunogenic composition comprising a varicella zoster virus antigen, wherein the varicella zoster virus antigen has the sequence of SEQ ID No. 9, and a compound of Formula I-4:
or a pharmaceutically acceptable salt thereof.
16 . The method of claim 15 ,
wherein the compound of Formula I-4 is in free acid form.
17 . The method of claim 15 ,
wherein the compound of Formula I-4 is in choline salt form.
18 . The method of claim 15 ,
further comprising a TLR4 agonist.
19 . The method of claim 18 ,
further comprising a liposome-forming compound.
20 . The method of claim 19 ,
wherein the liposome-forming compound forms liposomes containing the TLR4 agonist.
21 . The method of claim 19 ,
wherein the liposome-forming compound is selected from the group consisting of DOPC, DMPC, DMPG, cholesterol, and combinations thereof.
22 . The method of claim 18 ,
further comprising an emulsion.
23 . The method of claim 22 ,
wherein the emulsion is an oil-in-water emulsion.
24 . The method of claim 22 ,
wherein the emulsion contains the compound of Formula I-4 or pharmaceutically acceptable salt thereof.
25 . The method of claim 24 ,
wherein the emulsion contains the TLR4 agonist.
26 . The method of claim 20 ,
further comprising an emulsion.
27 . The method of claim 26 ,
wherein the emulsion is an oil-in-water emulsion.
28 . The method of claim 26 ,
wherein the emulsion contains the compound of Formula I-4 or pharmaceutically acceptable salt thereof.